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Abstract: 
Background and objectives: Incomplete distal renal tubular acidosis is a 
well-known cause of calcareous nephrolithiasis but the prevalence is 
unknown, mostly due to lack of accepted diagnostic tests and criteria. The 
ammonium chloride test is considered as gold standard for the diagnosis of 
incomplete distal renal tubular acidosis, but the furosemide/fludrocortisone 
test was recently proposed as an alternative. Due to the lack of rigorous 
comparative studies, the validity of the furosemide/fludrocortisone test in 
stone formers remains unknown. In addition, the performance of 
conventional, non-provocative parameters in predicting incomplete distal 
renal tubular acidosis has not been studied.  
Design, setting, participants, and measurements: We conducted a 
prospective study in an unselected cohort of 170 stone formers that 
underwent sequential ammonium chloride and furosemide/fludrocortisone 
testing.  
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Results: Using the ammonium chloride test as gold standard, the 
prevalence of incomplete distal renal tubular acidosis was 7.78 %. 
Sensitivity and specificity of the furosemide/fludrocortisone test FF 
test   were 77 % and 85 %, respectively, yielding a positive predictive 
value of 30 % and a negative predictive value of 98 %. Testing of several 
non-provocative clinical parameters in the prediction of incomplete distal 
renal tubular acidosis revealed fasting morning urinary pH and plasma 
potassium as the most discriminative parameters. The combination of a 
fasting morning urinary threshold pH <5.3 with a plasma potassium 
threshold >3.8 mmolmEq/l yielded a negative predictive value of 98 % 
with a sensitivity of 85 % and a specificity of 77 % for the diagnosis of 
incomplete distal renal tubular acidosis.  
Conclusions: The furosemide/fludrocortisone test can be used for 
incomplete distal renal tubular acidosis screening in stone formers, but an 
abnormal furosemide/fludrocortisone test result needs confirmation by 
ammonium chloride testing. Our data furthermore indicate that incomplete 
distal renal tubular acidosis can reliably be excluded in stone formers by 
use of non-provocative clinical parameters.    
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ABSTRACT 
Background and objectives: Incomplete distal renal tubular acidosis is a well-known cause 
of calcareous nephrolithiasis but the prevalence is unknown, mostly due to lack of accepted 
diagnostic tests and criteria. The ammonium chloride test is considered as gold standard for 
the diagnosis of incomplete distal renal tubular acidosis, but the furosemide/fludrocortisone 
test was recently proposed as an alternative. Due to the lack of rigorous comparative studies, 
the validity of the furosemide/fludrocortisone test in stone formers remains unknown. In 
addition, the performance of conventional, non-provocative parameters in predicting 
incomplete distal renal tubular acidosis has not been studied.  
Design, setting, participants, and measurements: We conducted a prospective study in an 
unselected cohort of 170 stone formers that underwent sequential ammonium chloride and 
furosemide/fludrocortisone testing.  
Results: Using the ammonium chloride test as gold standard, the prevalence of incomplete 
distal renal tubular acidosis was 8 %. Sensitivity and specificity of the 
furosemide/fludrocortisone test were 77 % and 85 %, respectively, yielding a positive 
predictive value of 30 % and a negative predictive value of 98 %. Testing of several non-
provocative clinical parameters in the prediction of incomplete distal renal tubular acidosis 
revealed fasting morning urinary pH and plasma potassium as the most discriminative 
parameters. The combination of a fasting morning urinary threshold pH <5.3 with a plasma 
potassium threshold >3.8 mEq/l yielded a negative predictive value of 98 % with a sensitivity 
of 85 % and a specificity of 77 % for the diagnosis of incomplete distal renal tubular acidosis. 
Conclusions: The furosemide/fludrocortisone test can be used for incomplete distal renal 
tubular acidosis screening in stone formers, but an abnormal furosemide/fludrocortisone test 
result needs confirmation by ammonium chloride testing. Our data furthermore indicate that 
incomplete distal renal tubular acidosis can reliably be excluded in stone formers by use of 
non-provocative clinical parameters.   
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INTRODUCTION 
Incomplete distal renal tubular acidosis (dRTA) is a condition characterized by defective 
urinary acidification capacity in the absence of systemic metabolic acidosis. The entity was 
first described by Wrong and Davies in 1959 who reported 3 patients that were unable to 
maximally acidify their urine upon administration of an oral acid load (100 mg [1.86 mmol] 
ammonium chloride/kg body weight) 
1
. Based on this study the one day single dose (“short”) 
ammonium chloride loading test became the “gold standard” for diagnosis 
1
. Typically, a pH 
< 5.3 has been accepted as threshold to rule out dRTA but there has never been a clear 
consensus on this threshold pH and various other definitions have been employed in the past 
2-8
. Using non-uniform definitions and provocative test procedures, a wide range of 
prevalence of incomplete dRTA from 2 to 21 % have been reported in recurrent stone formers 
3, 9, 10
.  
Provocative urinary acidification testing is not routinely conducted at most stone clinics but 
most clinics have routine clinical data on their patients with nephrolithiasis. How well do 
conventional non-provocative clinical parameters perform in the prediction of incomplete 
dRTA is not known and previous recommendations have been based primarily on expert 
opinions rather than data 
10, 11
. Even when the short ammonium chloride loading test can be 
performed in some centers, gastrointestinal side effects occur frequently after ammonium 
chloride ingestion. In 2007, Walsh et al. described an alternative provocation of distal 
acidification, the furosemide/fludrocortisone test, which is better tolerated than the 
ammonium chloride loading test 
12
. In a study that included 10 patients with nephrolithiasis or 
nephrocalcinosis (all without dRTA), Viljoen et al. observed a high false positive rate of 
incomplete dRTA diagnosis with the furosemide/fludrocortisone test compared to the gold 
standard ammonium chloride test, but fludrocortisone was given 10 h prior to test start and 
not simultaneously, as described by Walsh et al. 
12, 13
.  Thus, due to the current lack of 
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adequately powered well-controlled comparative studies, the validity of the 
furosemide/fludrocortisone test in uncovering incomplete dRTA in stone formers remains 
unknown.  
To address the issues outlined above, we compared clinical non-provocative parameters and 
the furosemide/fludrocortisone test results to the standard short ammonium chloride test in an 
unselected group of stone formers referred to our clinic for metabolic stone work-up. 
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MATERIALS  AND  METHODS 
 
Study design and study population 
This was a prospective comparative study. Study participants were recruited from stone 
formers referred to the Division of Nephrology and Hypertension at the Bern University 
Hospital between September 2012 and June 2016. Inclusion criteria were: i) ≥ 1 kidney stone 
episodes, ii) age ≥ 18 and iii) written informed consent. Exclusion criteria were: i) active 
urinary tract infection, ii) intake of medications known to interfere with urinary acidification, 
iii) pregnancy or lactation. Failure to acidify urinary pH < 5.3 in the ammonium chloride test 
was considered diagnostic for incomplete dRTA diagnosis. Complete dRTA was defined as 
presence of a pathological urinary acidification test with a concomitant metabolic acidosis in 
the morning fasting blood gas analysis (blood pH < 7.35 and blood bicarbonate < 21 mEq/l). 
Patients with an abnormal urinary acidification test without metabolic acidosis were 
considered to have incomplete dRTA. No sample size calculation was performed before start 
of the study because i) the prevalence of idRTA in our referred patients was not known and ii) 
absence of data with respect to the performance of the furosemide/fludrocortisone test in the 
diagnosis of idRTA in an unselected cohort of stone formers. The study was approved by the 
Ethical Committee of the Kanton Bern (approval # 90/12), registered at ClinicalTrials.gov 
(NCT01690039) and conducted in accordance with the Declaration of Helsinki. 
 
Data collection and measurements 
Metabolic work-up for stone disease included two 24 h urines on a random outpatient diet. 
Urine and blood analyses were performed at the Central Laboratory of the University Hospital 
of Bern, Switzerland using standard laboratory methods. Urine pH in 24 h urines was 
measured by a S20 SevenEasy pH meter (Mettler Toledo, Greifensee, Switzerland). Estimated 
glomerular filtration rate (eGFR) was calculated according to CKD-EPI (Chronic Kidney 
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Disease Epidemiology Collaboration) [28]. Diabetes was defined as reported, treated, fasting 
glycemia ≥126 mg/dl, or random glycemia ≥200 mg/dl. Hypertension was defined as 
reported, treated, a mean systolic blood pressure ≥140 mmHg, or a mean diastolic blood 
pressure ≥90 mmHg. 
 
Ammonium chloride and furosemide/fludrocortisone tests 
All participants underwent sequential ammonium chloride and furosemide/fludrocortisone 
testing, at least 1 week and at most 1 month apart, regardless of 24 h or fasting urinary pH or 
type of stone, thereby constituting a completely unselected population of calcareous stone 
formers. The short one day ammonium chloride loading test and the 
furosemide/fludrocortisone test were performed as previously described 
1, 12
. Study 
participants fasted after midnight and throughout the tests. For the ammonium chloride test, 
ammonium chloride gelatin capsules (100 mg/kg body weight) were given at 0800 h with 
water in the presence of the nursing staff over a period of 30 minutes. During the test, fluid 
intake was ad libitum. Venous blood samples were obtained for chemistry, pH and blood 
gases at 0800, 1000, 1200 h. Urine was collected hourly from 0800 to 1400 h. For the 
furosemide/fludrocortisone test, furosemide (40 mg) and fludrocortisone (1 mg) were given at 
0800 h with water in the presence of the nursing staff. During the test, fluid intake was ad 
libitum. Venous blood samples were obtained for chemistry, pH and blood gases at 0800, 
1100, 1300 h. Urine was collected hourly from 0800 to 1300 h. Venous blood gas and 
electrolyte analysis was performed immediately after collection on a ABL800FLEX blood gas 
analyzer (Radiometer, Thalwil, Switzerland). Urine pH was measured by a S20 SevenEasy 
pH meter and urinary pCO2 by an ABL700 blood gas analyzer (Radiometer, Thalwil, 
Switzerland) immediately after collection. 
 
Statistical analysis 
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Statistical analyses were conducted using the R software, version 3.2.2 
14
. All statistical tests 
were two-sided and a p value <0.05 was considered as statistically significant. Agreement 
between the two urinary acidification tests was analyzed by the Bland–Altman method using 
the R package “BlandAltmanLeh”
 15
. ROC analysis was done using the R package “pROC” 
16
. The sensitivity-specificity versus nadir urinary pH plot (Fig. 1F) was done by using the R 
package “OptimalCutpoints” 
17
. The associations of the nadir urinary pH with 24 h citraturia 
and with calciuria were visually assessed by cubic spline functions of the nadir urinary pH 
and by boxplots stratifying the nadir urinary pH at different thresholds.  
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RESULTS 
Characteristics of study population 
Two of the 170 individuals recruited had complete dRTA and were excluded from the final 
analysis. Baseline characteristics of the remaining 168 participants are depicted in Table 1. 
Median age of the study population was 45 years, 73 % of participants were men. The 
majority of individuals (76 %) had ≥ 2 symptomatic stone events, stone analysis was available 
in 83 % of individuals. Baseline blood and urinary biochemistries are depicted in Suppl. 
Table 1.  
 
Phenotype of stone formers according to nadir urinary pH 
Thirteen participants (8 %) in the ammonium chloride test and 33 participants (20 %) in the 
furosemide/fludrocortisone test had a nadir urinary pH ≥ 5.3. Baseline characteristics of stone 
formers, listed separately by test and nadir urinary pH are depicted in Table 2. Stone formers 
with nadir urinary pH ≥ 5.3 in the ammonium chloride test had a lower BMI (p=0.02). Kidney 
stones of participants with nadir urinary pH ≥ 5.3 in both test were less likely to contain 
calcium oxalate but more likely to contain calcium phosphate. None of the stones of 
participants with nadir urinary pH ≥ 5.3 contained uric acid. Stone formers with nadir urinary 
pH ≥ 5.3 in the ammonium chloride test displayed a significantly lower plasma potassium and 
24 h citrate excretion, while 24 h urea excretion (a measure of daily protein intake), net 
gastrointestinal alkali absorption (an arithmetic estimate of daily alkali intake) and kidney 
function were similar in subjects with nadir urinary pH <5.3 or ≥ 5.3 (Table 3) 
18
. 
 
How well do non-provocative parameters perform in predicting incomplete dRTA ? 
To this end, we tested the performance of the non-provocative parameters morning fasting 
urinary pH, plasma potassium, plasma bicarbonate, 24 h citraturia and stone calcium 
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phosphate content in the prediction of incomplete dRTA, defined by nadir urinary pH ≥ 5.3 in 
the ammonium chloride test. Second morning fasting urinary pH instead of 24 h urinary pH 
was chosen since correlation of the nadir urinary pH in the ammonium chloride test was better 
with the fasting morning urinary pH than the 24 h urinary pH (Suppl. Fig. 1). Receiver 
operating characteristic (ROC) analysis revealed that a second morning fasting urinary pH 
and plasma potassium had the highest individual area under the curve (AUC) for the 
prediction of incomplete dRTA, and a combination of the two parameters - second fasting 
morning urinary pH and plasma potassium - further increased the AUC (Suppl. Fig. 2). 
Combination of a fasting morning urinary threshold pH of <5.3 and a plasma potassium 
threshold of >3.8 mmol/l yielded a negative predictive value of 98 % and a positive predictive 
value of 24 % for the diagnosis of incomplete dRTA (Table 4 A). Use of higher urinary pH 
threshold caused a significant decrease of specificity, use of a higher plasma potassium 
thresholds resulted in significantly lower negative predictive values (not shown).  
 
Performance of the FF test in the diagnosis of incomplete dRTA in stone formers 
Utilizing the ammonium chloride test as gold standard, sensitivity and specificity of the 
furosemide/fludrocortisone test were 77 % and 85 %, respectively, yielding a positive 
predictive value of 30 % and a negative predictive value of 98 % for the diagnosis of dRTA, 
respectively (Table 4 B). Distribution of nadir urinary pH values for both tests are depicted as 
histograms with kernel density plots in Figs. 1 A and B. In both tests, there was no evidence 
for a bimodal distribution of the urinary pH nadir values. Statistical test comparison revealed 
a highly significant though only moderately positive linear relationship between the nadir 
urinary pH values of the two tests (Fig. 1 C). The absolute mean-difference plot (Bland-
Altman plot) for the two tests is depicted in Fig. 1 D. The mean bias was +0.025 pH units, the 
lower and upper limits of agreement were -0.87 and 0.92, respectively and contained 160 of 
the 168 data points (95 %), as expected in case of a normal distribution 
19, 20
. There was a 
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tendency to more positive differences at higher pH nadir values, i.e. an increase in bias with 
magnitude as shown by the positive slopes of linear regression lines in Fig. 1 D. The AUC of 
the ROC analysis was 0.88 (CI 0.79 – 0.97) (Fig. 1 E). The sensitivity-specificity versus nadir 
urinary pH plot analysis yielded an optimal threshold nadir urinary pH of 5.19 for the 
furosemide/fludrocortisone test at a sensitivity and specificity threshold of 85 % and 81 %, 
respectively, which is close to the currently employed threshold urinary pH < 5.3 (Fig. 1 F).  
Pooled urine and blood analytes, separated by test and nadir urinary pH are depicted in Figs. 2 
and 3, respectively. Consistent with previous reports 
1, 12
, we observed that the nadir urinary 
pH was achieved at ~3 h in the furosemide/fludrocortisone test and at ~5 h in the ammonium 
chloride test (Figs. 2 A, F). As shown in Fig. 2 B-E, participants with a nadir urinary pH ≥ 
5.3 in the ammonium chloride test displayed lower hourly urinary sodium, chloride and 
ammonium excretions while the urinary volume was unaltered. In the 
furosemide/fludrocortisone test participants with a nadir urinary pH ≥ 5.3 also displayed 
reduced hourly urinary sodium and chloride excretions, but only in the second half of the 
furosemide/fludrocortisone test (Figs. 2 H, I). In contrast, urinary ammonium excretions in 
the furosemide/fludrocortisone test were similar in both groups of patients (Fig. 2 J) and 
urinary volumes were higher in participants with a nadir urinary pH ≥ 5.3 (Fig. 2 G). 
As expected, the administration of ammonium chloride resulted in a large decrease of venous 
pH and bicarbonate compared to baseline (systemic acid load) (Figs. 3 A, B), whereas the 
administration of furosemide and fludrocortisone caused a small increase of venous pH and 
bicarbonate compared to baseline (increase of urinary acid excretion) (Figs. 3 C, D). During 
the ammonium chloride and furosemide/fludrocortisone tests, venous pH was not 
significantly different between participants with nadir urinary pH < 5.3 and ≥ 5.3 at all time 
points measured. However, venous bicarbonate was significantly higher at baseline and at 4 h 
during the ammonium chloride test in participants with nadir urinary pH ≥ 5.3 (Figs. 3 A, B). 
In contrast, venous pH and bicarbonate were not different between participants with nadir 
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urinary pH < 5.3 and ≥ 5.3 during the furosemide/fludrocortisone test at all time points tested 
(Figs. 3 D, E).  
 
Is the nadir pH 5.3 for the diagnosis of incomplete dRTA justified ? 
Our results indicate that urinary acidification capacity is a continuous trait in stone formers. In 
addition to alkaline urinary pH, hypocitraturia and hypercalciuria are important prolithogenic 
factors frequently encountered in dRTA patients. As the next step, we analyzed the 
association of the nadir urinary pH in the ammonium chloride test with 24 h calciuria or 24 h 
citraturia. As shown in Figs. 4 A and C, with increasing nadir urinary pH, citrate excretion 
decreased and calcium excretion increased. Using the established pH < 5.3 for diagnosis, 
citraturia was significantly lower in participants with incomplete dRTA (Fig. 4 B). However, 
24 h calciuria was not different between participants with and without incomplete dRTA at 
this pH threshold (Fig. 4 D). We next performed these analyses at different arbitrarily defined 
urinary nadir pH thresholds ranging from pH 5.1 to 5.5. As shown in Suppl. Fig. 3, a pH < 
5.3 was the only threshold pH which allowed a separation of the two groups of participants on 
the basis of citraturia. In contrast, at all pH thresholds tested, calciuria was not different 
between the two groups of participants.  
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DISCUSSION 
This is the first controlled study that rigorously compared the performance of the 
furosemide/fludrocortisone test and non-provocative parameters with the gold standard 
ammonium chloride test for the diagnosis of incomplete dRTA in stone formers. One 
important feature of this study compared to previous studies is the fact that we recruited stone 
formers without preselection into study, i.e. regardless of fasting or 24 h urinary pH, stone 
type or presence of hypocitraturia or hypercalciuria. The use of unselected patient population 
renders our results applicable to general kidney stone practices. The results of our study 
suggest that incomplete dRTA can be reliably excluded by use of the non-provocative 
parameters which includes second morning fasting urinary pH and plasma potassium. If a 
provocative test is required, the furosemide/fludrocortisone test has excellent negative 
predictive value. If incomplete dRTA cannot be excluded by either approach, the diagnosis 
can then be confirmed by ammonium chloride testing. 
24 h urinary pH and prevalence of calcium phosphate containing stones were significantly 
higher in stone formers with nadir urinary pH ≥ 5.3 in the furosemide/fludrocortisone test. 
Similar results were obtained with the ammonium chloride test, but the difference did not 
quite reach statistical significance. In contrast, uric acid calculi, typically associated with low 
urinary pH, were not observed at all in stone formers with incomplete dRTA defined by either 
tests 
21
. This finding corroborates with previous studies that reported an association of a 
urinary acidification deficit with calcium phosphate-containing stones 
22-24
. Interestingly, 
plasma potassium and 24 h citraturia were lower in stone formers with incomplete dRTA. The 
lower plasma potassium may at least partially explain the reduction in citraturia via a 
reduction of proximal tubular pH which is well known in potassium deficiency 
25
. The 
pathogenesis and etiology of the reduced plasma potassium remains unclear, 24 h urinary 
excretions of sodium and potassium were similar in both groups of patients.  
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Our surprising observation that stone formers with incomplete dRTA had a higher venous 
bicarbonate stands in contradiction to a recent study that reported results of urinary 
acidification testing in 57 individuals with primary Sjögren’s syndrome 
26
. Patients with 
primary Sjögren’s syndrome and incomplete dRTA had lower venous pH and bicarbonate 
compared to patients with primary Sjögren’s syndrome without incomplete dRTA, but higher 
venous pH and bicarbonate compared to patients with primary Sjögren’s syndrome and 
complete dRTA. Although confirmation by longer term studies in primary Sjögren’s 
syndrome patients is lacking, such a constellation would be compatible with incomplete 
dRTA being a “pre-acidotic” forme fruste of complete dRTA. In contrast, our finding of an 
increased venous bicarbonate in individuals with incomplete dRTA suggests that the 
underlying pathophysiology in stone formers maybe different, as suggested previously 
27
.  
Importantly, our study reveals for the first time that urinary acidification capacity is not a 
dichotomous but a continuous trait in stone formers. This observation stands in contrast to the 
initial description by Wrong and Davies and the currently held opinion that incomplete dRTA 
represents a distinct entity with respect to urinary acidification capacity. Based on urinary 
citrate excretion, but not based on urinary acidification capacity or calcium excretion, a 
threshold pH < 5.3 can be justified for the diagnosis of incomplete dRTA. 
There are no randomized controlled trials in stone formers with incomplete dRTA. In small 
studies, treatment with alkali in adult stone formers with incomplete dRTA decreased 
hypercalciuria, increased citraturia and reduced stone formation 
28-30
. In stone formers with 
incomplete dRTA associated with medullary sponge kidney, alkali therapy also led to a 
decrease in stone passage and improvement of the associated bone disease 
31-33
. Results of 
these uncontrolled studies indicate that stone formers with incomplete dRTA constitute a 
unique subset of patients that may benefit from alkali treatment. However, alkali treatment 
was also effective in the prevention of recurrence in unselected cohorts of patients with 
calcareous nephrolithiasis 
34
. Thus, clearly, longitudinal and interventional trials are needed to 
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further explore the prognostic and therapeutic relevance of diagnosing incomplete dRTA in 
stone formers. 
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TABLES 
  
Table 1. Baseline characteristics of study population. The available number of 
participants is indicated for each characteristic. Categorical variables are described 
by % and continuous variables by their median (IQR; 25
th
-75
th
 quantile). 
Characteristics   N All participants 
Male   123 73% 
Age (yr)   168 45 (34-55) 
BMI (kg/m
2
)   168 27 (24-30) 
Current or former smoker       
  Yes   75 45 % 
  Unknown   17 10 % 
Hypertension   90 54 % 
Diabetes   14 8 % 
 Number of stone symptomatic events       
  1 event   41 24 % 
  2 events   42 25 % 
  3 events   33 20 % 
  ≥4 events   52 31 % 
Positive family history of kidney stones    85 53 % 
Participants with available stone analysis 140 83 % 
Kidney stone composition (containing)       
  Calcium oxalate   129 77 % 
  Calcium phosphate   59 35 % 
  Struvite   6 4 % 
  Uric acid   10 6 % 
  Cystine   1 1 % 
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Table 2. Baseline characteristics according to nadir urinary pH in furosemide/fludrocortisone and ammonium chloride tests. The available number of participants is indicated 
for each characteristic, stratified for nadir urinary pH. Categorical variables are described by % and continuous variables by their median (25
th
-75
th
 quantile). Between-group differences 
were determined by Mann–Whitney U, chi-squared test or Fisher's exact test (if expected number of observations per cell is <5) as appropriate and the corresponding P values are 
indicated. 
Characteristics 
Furosemide / Fludrocortisone  test   Ammonium chloride test 
N Nadir pH <5.3 N Nadir pH ≥ 5.3 P value   N Nadir pH <5.3 N Nadir pH ≥ 5.3 P value 
Male 100 74 % 23 70 % 0.77   116 75 % 7 54 % 0.19 
Age at first presentation (yr) 135 46 (34-57) 33 42 (31-51) 0.14   155 46 (34-56) 13 38 (31-51) 0.14 
BMI at first presentation, kg/m
2
 135 27 (24-30) 33 25 (22-29) 0.08   155 27 (24-30) 13 23 (19-27) 0.02 
Current or fomer smoker                       
  yes 57 42 % 18 55 % 
0.14 
  69 45% 6 46 % 
0.24 
  unknown 12 9 % 5 15 %   14 9 % 3 23 % 
Hypertension 76 56 % 14 42 % 0.40   85 55 % 5 39 % 0.40 
Diabetes 13 10 % 1 3 % 0.31   14 9 % 0 0 % 0.60 
Age at first stone event (yr) 127 33 (26-42) 30 30 (23-38) 0.24   144 33 (26-42) 13 28 (22-34) 0.21 
Age at first available stone analysis (yr) 104 45 (33-55) 25 38 (31-50) 0.22   118 45 (34-54) 11 37 (26-49) 0.16 
Number of stone symptomatic events                       
  1 event 32 24 % 9 27 % 
0.38 
  36 24 % 5 39 % 
0.19 
  2 events 33 24 % 9 27 %   38 25 % 4 31 % 
  3 events 30 22 % 3 9 %   33 20 % 0 0 % 
  ≥4 events 40 30 % 12 36 %   48 31 % 4 31 % 
Positive family history of kidney stones 69 53 % 16 52 % 1   77 52 % 8 62 % 0.69 
Participants with available stone analysis 113 84 % 29 88 % 0.79   131 85 % 11 85 % 1 
Stone composition (containing)                       
  Calcium oxalate 107 96 % 23 79 % 0.01   122 94 % 8 73 % 0.04 
  Calcium phosphate 38 34 % 22 76 % <0.01   52 40 % 8 73 % 0.05 
  Struvite 3 3 % 3 10 % 0.10   5 4 % 1 9 % 0.39 
  Uric acid 10 9 % 0 0 % 0.12   10 8 % 0 0 % 1 
  Cystine 0 0 % 1 3 % 0.21   1 1 % 0 0 % 1 
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Table 3.  Blood and urinary parameters according to nadir urinary pH in furosemide/fludrocortisone and ammonium chloride tests. The available number of participants is indicated for each characteristic, 
stratified for nadir urinary pH. Variables are described by their median (25
th
-75
th
 percentile). Between-group differences are determined by Mann-Whitney U test and the corresponding P values are indicated. NGIA: net 
gastrointestinal alkali absorption. 
Characteristic Normal range Unit 
Furosemide / Fludrocortisone  test   Ammonium chloride test 
N Nadir pH <5.3 N Nadir pH ≥ 5.3 P value   N Nadir pH <5.3 N Nadir pH ≥ 5.3 P value 
Plasma                           
  Sodium 135 - 145 mEq/L 135 141 (139-142) 33 141 (140-142) 0.95   155 141 (139-142) 13 141 (141-141) 0.25 
  Potassium 3.5 – 5.0 mEq/L 135 4.0 (3.7-4.2) 33 3.8 (3.6-4.1) 0.06   155 4 (3.7-4.2) 13 3.6 (3.5-3.8) <0.01 
  Chloride 97 - 108 mEq/L 134 103 (102-105) 33 103 (101-105) 0.53   154 103 (102-105) 13 102 (102-103) 0.26 
  Calcium corrected 8.9 – 10.1 mg/dl  133 9.4 (9.1-9.6) 33 9.4 (9.1-9.7) 0.95   153 9.4 (9.1-9.6) 13 9.2 (9-10) 0.89 
  Phosphate 2.5 – 4.5 mg/dl  135 3.1 (2.7-3.4) 32 3.1 (2.7-3.3) 0.88   154 3.1 (2.7-3.4) 13 3.2 (2.8-3.6) 0.39 
  Magnesium 1.8 – 2.6 mg/dl  135 2.0 (1.9-2.0) 33 2.0 (1.9-2.0) 0.23   155 2 (1.9-2.1) 13 2 (1.9-2) 0.66 
  Creatinine 0.6 – 1.4 mg/dl 135 0.9 (0.8-1.0) 33 0.9 (0.8-1.0) 0.74   155 0.9 (0.8-1) 13 0.9 (0.8-1) 0.76 
  eGFR >90 ml/min per 1.73 m
2
 135 99 (87-109) 33 98 (86-110) 0.95   155 99 (87-109) 13 91 (84-115) 0.61 
  Urea nitrogen 6 – 20 mg/dl  133 14 (12-17) 33 14 (12-16) 0.80   153 14 (12-17) 13 14 (12-15) 0.51 
  Uric acid 3 – 7 mg/dl  134 5.5 (4.4-6.5) 33 5.7 (4.7-6.3) 0.68   154 5.5 (4.5-6.5) 13 5.5 (4.0-5.8) 0.35 
  Alkaline phosphatase 35 - 100 U/L 135 63 (53-75) 33 60 (54-71) 0.60   155 62 (53-73) 13 59 (52-70) 0.73 
Urine                           
  Sodium 50 - 150 mEq/24 h 124 168 (130-212) 32 159 (133-205) 0.71   143 167 (130-213) 13 153 (114-177) 0.26 
  Potassium 20 - 120 mEq/24 h 123 57 (49-70) 32 68 (41-85) 0.41   142 58 (49-72) 13 58 (33-79) 0.86 
  Chloride 70 - 250 mEq/24 h 122 151 (121-201) 32 137 (109-191) 0.23   141 149 (121-202) 13 123 (89-163) 0.12 
  Calcium 100 - 300 mg/24 h  124 221 (145-288) 32 229 (202-305) 0.17   143 222 (151-294) 13 230 (197 -276) 0.41 
  Phosphate 0.6 – 1.4 g/24 h  124 0.9 (0.7-1.0) 32 0.8 (0.6-1.0) 0.38   143 0.9 (0.7-1) 13 0.8 (0.6-0.9) 0.16 
  Magnesium 30 - 120 mg/24 h  123 113 (90-148) 32 109 (95-137) 0.76   142 113 (92-146) 13 109 (88-136) 0.56 
  Creatinine 0.8 - 2 g/24 h  124 1.5 (1.3-1.8) 32 1.5 (1.2-1.7) 0.83   143 1.5 (1.3-1.8) 13 1.4 (1.1-1.7) 0.36 
  Urea nitrogen 6–14 g/24 h  123 10 (9-13) 32 9 (8-12) 0.28   142 10 (8-13) 13 9 (7-10) 0.14 
  Uric acid < 750 mg/24 h  124 527 (414-637) 32 513 (394-617) 0.69   143 534 (413-642) 13 475 (376-549) 0.23 
  pH 5.8 – 6.2  ─ 85 5.9 (5.3-6.5) 23 6.4 (5.7-7.0) 0.02   97 5.9 (5.3-6.5) 11 6.3 (5.8-7.0) 0.11 
  Anion gap  ─ mEq/L 133 38 (29-48) 33 38 (31-45) 1.00   153 37 (29-47) 13 39 (33-48) 0.44 
  Citrate > 320 mg/24 h  120 455 (307-666) 32 492 (324 -636) 0.97   139 482 (315-657) 13 332 (134-388) 0.02 
  NGIA  ─ mEq/24 h 108 31 (15-44) 30 40 (27-54) <0.01   126 33 (19-46) 12 38 (21-53) 0.38 
  Oxalate 20 - 40 mg/24 h  120 22 (16-30) 32 30 (17-33) 0.07   139 23 (16-31) 13 28 (24-33) 0.29 
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Table 4. Performance of non-provocative clinical parameters (A) and of furosemide/fludro-
cortisone testing (B) in the prediction of incomplete dRTA in stone formers. A second morning 
fasting urinary pH < 5.3 and a plasma potassium > 3.8 mEq/L were used as non-provocative 
thresholds. In parentheses, 95 % CIs are indicated for sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV).  
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FIGURE LEGENDS 
Figure 1. Comparison of ammonium chloride and furosemide/fludrocortisone test 
results. 
A) Histogram of urinary pH nadir in furosemide/fludrocortisone test with Kernel density plot. 
B) Histogram of urinary pH nadir in ammonium chloride test with Kernel density plot. C) 
Association of ammonium chloride test and furosemide/fludrocortisone test nadir urinary pH 
values. The regression line (solid black line) with 95 % CI (grey area) was created by a linear 
model. Dashed lines indicate the pH threshold of 5.3 on both axes. D) Bland-Altmann plot 
with regression lines for participants without (black line) or with incomplete dRTA (grey 
line). Horizontal dashed lines indicate upper and lower limits of agreement calculated as the 
95 % CI around the mean bias (horizontal solid line). E) ROC curve for the 
furosemide/fludrocortisone test. Dashed lines around the ROC curve indicate the 95% CI of 
the sensitivity at the given specificity points. The AUC and its 95% CI is indicated. F) 
Sensitivity-specificity versus nadir urinary pH plot indicate the nadir urinary pH threshold in 
the furosemide/fludrocortisone test where sensitivity and specificity are simultaneously 
maximized. 
 
Figure 2. Time course of urinary parameters separated in participants with nadir 
urinary pH <5.3 and ≥ 5.3. Grey bars indicate nadir urinary pH < 5.3, black bars indicate 
nadir urinary pH ≥ 5.3. Values shown are medians and IQR. Between group differences were 
determined by Mann–Whitney U test. *p < 0.05. **p < 0.01. A) Time course of urinary pH in 
the ammonium chloride test, the dashed line indicates the diagnostic threshold pH 5.3. B) - E) 
Time course of urinary volume, sodium, chloride and ammonium in the ammonium chloride 
test. F) Time course of urinary pH in the furosemide/fludrocortisone test, the dashed line 
indicates the diagnostic threshold pH 5.3. G) – J) Time course of urinary volume, sodium, 
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chloride and ammonium in the furosemide/fludrocortisone test. Furosemide/fludrocortisone 
tests lasted 5 h, ammonium chloride tests lasted 6 h.  
 
Figure 3. Time course of blood parameters separated in participants with nadir urinary 
pH <5.3 and ≥ 5.3. Blood was drawn at baseline and at 2 h and 4 h in ammonium chloride-
tests, and at baseline and at 3 h and 5 h in the furosemide/fludrocortisone tests. Grey bars 
indicate nadir urinary pH < 5.3, black bars indicate nadir urinary pH ≥ 5.3. Values shown are 
medians and IQR. Between group differences were determined by Mann–Whitney U test. *p 
< 0.05. **p < 0.01. A) and B) Time course of venous blood pH and venous bicarbonate in the 
ammonium chloride test. C) and D) Time course of venous blood pH and venous bicarbonate 
in the furosemide/fludrocortisone test. 
 
Figure 4. Association of nadir urinary pH with 24 h citraturia and calciuria. A) and C) 
Associations of nadir urinary pH in the ammonium chloride test with 24 h citraturia and with 
24 h calciuria, respectively. Black lines in Fig. A and C indicate the cubic spline function of 
the association. Grey shaded areas represent the 95% CI for the fitted splines. Vertical dashed 
lines indicate the diagnostic threshold pH 5.3. B) and D) 24 h citraturia and 24h calciuria  
separated in participants with and without incomplete dRTA. Box plots indicate 25
th
, 50
th
 and 
75th quantile of the distribution of the 24 h excretion for each group. Whiskers above and 
below the box indicate the 1.5 × IQR: [25
th
 – 1.5×IQR] and [75
th
 + 1.5×IQR], respectively. 
Between group differences were determined by Mann–Whitney U test.  
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